Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?


In the course of the last decade the therapy of renal cell carcinoma (RCC) stepped into a new era as targeted therapies changed protocols and the prognosis of patients as well. Could this successful start with sunitinib and sorafenib be continued by more potent agents? Because objective response rates (ORR) are still far from ideal (none of them reach 50… (More)
DOI: 10.3978/j.issn.2223-4683.2012.06.07


  • Presentations referencing similar topics